Publications by authors named "P E Pickens"
We present a rare case of prostatic endobronchial metastases that was successfully treated with total androgen blockade (TAB). This case demonstrates prolonged remission on continuous TAB and continued remission employing intermittent therapy.
View Article and Find Full Text PDFBACKGROUND Antiphospholipid syndrome (APS) is an autoimmune disease characterized by antibodies directed against phospholipids on plasma membranes. Through unclear mechanisms, APS confers hypercoagulability. APS may cause recurrent thromboses in the arterial and venous vasculature.
View Article and Find Full Text PDFArticle Synopsis
- - A study found that Ibrutinib offers better response rates and survival for chronic lymphocytic leukemia (CLL) patients not included in earlier trials, particularly those under 65 and with a specific chromosome deletion (del[17p13]).
- - Out of 391 CLL patients examined, 57% were excluded from previous pivotal studies, with 41% being under 65 and 30% having del(17p13), showing that those under 65 were more likely to start on a higher dose of Ibrutinib, impacting their progression-free survival (PFS).
- - Common side effects included fatigue and rash, with 24% of patients stopping the treatment within about 14 months, often
Article Synopsis
- Venetoclax is a BCL2 inhibitor used to treat chronic lymphocytic leukemia (CLL) patients with specific genetic mutations, showing effectiveness even after previous kinase inhibitor treatments.
- A study of 141 CLL patients revealed a 72% overall response rate to Venetoclax, with common side effects including neutropenia and thrombocytopenia, but many patients reached the maximum recommended dosage.
- Further research is needed to determine the best order for using newer CLL therapies, as many patients successfully transitioned to other treatments like ibrutinib after stopping Venetoclax.
Results from several recent studies in chronic lymphocytic leukemia (CLL) have demonstrated an association between ibrutinib exposure and the development of atrial fibrillation, estimated incidence of 11% with long-term follow up. This is a common cause of ibrutinib discontinuation. Risk factors for atrial fibrillation include advanced age, hypertension (HTN), mitral valve disease (MVD), left atrial remodeling, coronary artery disease (CAD) and risk factors for cardiovascular dysfunction We conducted a retrospective case control study using the presence of left atrial abnormality identified on pre-ibrutinib EKGs, defined as either (1) Lead II-bifed p wave, with 40 mcsec between peaks for ≥ 2.
View Article and Find Full Text PDF